METHOD OF PREDICTING EFFICIENCY OF NEOADJUVANT CHEMICAL THERAPY IN PATIENTS WITH RESECTABLE BASAL-LIKE TRIPLE-NEGATIVE BREAST CANCER Russian patent published in 2015 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to oncology, and can be used to predict efficiency of neoadjuvant chemical therapy (NACT) in patients with resectable basal-like triple-negative breast cancer. NACT efficiency in patients is calculated by formula: P=e^Y/(1+e^Y), where P is value of probability of sign development, Y is value of regression equation; e is mathematical constant, equal 2.72. Value of regression equation is determined by formula: Y=(42.8-1.86X1-9.3X2-2.14X3+3.19X4), where (42.8) is value of coefficient of free term regression; X1 represents subtypes of basal-like triple-negative cancer ( 1 - subgroup with expression of only CK 5/6; 2 is subgroup with expression of only EGFR1; 3 is subgroup with expression of CK 5/6 and EGFR1), (1.86) is the value of said sign regression coefficient; X2 is the level of EGFR1 expression in biopsy material (1 is high level, 2 is low level), (9.3) is the value of said sign regression coefficient; X3 is the level of expression of Ki-67 in biopsy material (1 is low level, 2 is high level), (2.14) is the value of said sign regression coefficient; X4 is chemical therapy scheme (1-FAC, 2-CAX), (3.19) is the value of said sign regression coefficient. If P<0.5, low efficiency of NACT is predicted, if P>0.5, high efficiency of NACT is predicted.

EFFECT: application of claimed method makes it possible to plan pre-operation treatment of patients with individualisation of approach to selection of chemical therapy.

4 ex, 4 tbl